Retrospective analysis and temporal dissection of the uncovered BCL2 variants in longitudinally collected patient samples revealed a heterogeneous and dynamically changing subclonal abundance of mutations during venetoclax therapy, suggesting a complex underlying architecture of resistant CLL cells, coupled with subsequent clinical disease progression in all four cases. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.